Jena French on Combinations With Immunotherapy in Thyroid Cancer

Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib (Lenvima) as treatment for patients with thyroid cancer.

Targeting PD-1 with monotherapy has been successful in several tumor types, French explains. However, it does not produce a complete response throughout an entire patient population. Additionally, lenvatinib has been shown to demonstrate good partial responses in patients; therefore, PD-1 antibodies and lenvatinib combined could show promising efficacy levels.

French says that combination therapies will become a bigger focus in the future treatment landscape of thyroid cancer.